In order to deliver a personalised, responsive service and to improve the site, we remember and store information about how you use it. This is done using simple text files called cookies which sit on your computer. By continuing to use this site and access its features, you are consenting to our use of cookies. To find out more about the way drugeruptiondata.com uses cookies please read our 'Cookie Policy'.
Adverse reactions attributed to entire drug class 'Antimycobacterial (including antitubercular)'
Please login to view adverse reactions.
Cutaneous adverse reaction (includes severe cutaneous adverse drug reaction (SCAR))
- (2023): Rizzi A+, Asian Pac J Allergy Immunol Oct, Online ahead of print [REVIEW]
- (2022): Modi B+, Indian J Tuberc 69(4), 470-475 (56 cases)
Alanine aminotransferase (ALT) increased
- (2024): Chen X+, J Clin Pharmacol Mar, Online ahead of print
- (2024): Quiroz-Aldave JE+, Expert Rev Endocrinol Metab Jan, Online ahead of print17% [REVIEW]
Metabolic syndrome (includes metabolic disorder)
- (2023): Lim J+, Open Forum Infect Dis Aug (e-Collection) (association)
Gastrointestinal disorder / discomfort
- (2018): Fei CM+, Malays J Med Sci 25(5), 1035% [REVIEW]
- (2020): Gezahegn LK+, PLoS One 15(11), e024134614%
Hepatotoxicity / liver injury / acute liver injury / drug-induced liver injury (DILI)
- (2025): Chen R+, J Gastrointestin Liver Dis 34(1), 55-63 (pharmacogenomics)
- (2025): Cheng J+, Int J Clin Pharm Feb, Online ahead of print [REVIEW] (pharmacogenomics)
- (2025): Zhang S+, Infect Drug Resist 18, 2065-2078 [REVIEW]
- (2024): He Q+, Br J Clin Pharmacol Oct, Online ahead of print (pharmacovigilance / pharmacoepidemiology)
- (2023): Akkahadsee P+, Sci Rep 13(1), 19880 [REVIEW]
- (2022): Jaramillo-Valverde L+, Mol Genet Genomic Med Jun, Online ahead of print (pharmacogenomics)
- (2022): Jaramillo-Valverde L+, Int J Mol Sci 23 (19), 11028 (pharmacogenomics)
- (2021): Becker MW+, World J Gastrointest Pharmacol Ther 12(3), 40-55 [REVIEW]
- (2021): Chanhom N+, Heliyon 7(4), e06852
- (2021): Huang YS+, J Chin Med Assoc Oct, Online ahead of print25%
- (2021): Jiang F+, Liver Int Apr, Online ahead of print5%
- (2021): Khiewkhern S+, Stud Health Technol Inform 281, 784-7886%
- (2021): Nataprawira HM+, Am J Case Rep 22, e930828 (6 cases)
- (2021): Zhu J+, J Clin Pharm Ther May, Online ahead of print
- (2020): Kumar PS+, EJIFCC 31(3), 242-247 (1 case / female)
- (2020): Radhika S+, Curr Drug Saf Jun, Online ahead of print14%
- (2020): Xu N+, Eur J Hosp Pharm Sep, Online ahead of print4%
- (2020): Yang M+, Pharmacol Res Perspect 8(6), e00696 [REVIEW]
- (2020): Zeleke A+, BMC Res Notes 13(1), 220%
Thrombocytopenia / platelets decreased
- (2023): Kaur A+, Indian J Tuberc 70(4), 489-496 [REVIEW]
Adverse effects / adverse reactions
- (2021): Trubnikov A+, Int J Environ Res Public Health 18(8) [REVIEW]
